MDSCs are key regulators of the immunosuppressive TME and impact virtually all types of cancer therapy. We and others have recently shown that selectively targeting MDSCs was sufficient to improve the therapeuti
Tumor counts in azoxymethane (AOM)/dextran sulfate sodium (DSS)-treated mice were specifically reduced by the administration of an anti-PD1 antibody, which inhibits PD-1 signaling [50]. These tumors exhibit a higher mutational burden and frequency of neoantigens, rendering them more susceptible to...
Figure 1. TEV PD-L1 mediates αPD-1 therapy resistance (A–C) Tumor volume of B16F10 or 4T1 tumor-bearing mice (A–C) or 4T1 Rab27a−/−, B16F10 Rab27a−/− (A and B), 4T1 Coro1a−/−, or B16F10 Coro1a−/− (C) tumor-bearing mice received αPD-1 treatment...
We assessed whether type I polarized dendritic cells (DC1) could improve checkpoint therapy in a preclinical model of HER2+ breast cancer. TUBO bearing mice were vaccinated with either MHC class I or class II HER2 peptide pulsed DC1 (class I or class II HER2-DC1) concurrently or sequentially ...
PD-1 blockade, which reinvigorates the tumor-reactive CD8+T cells by removing the inhibition induced by the interaction of PD-1 and PD-L1, has achieved high success in mediating complete, durable responses in patients with advanced or conventional therapy-resistant cancers; however, the successes...
Consistent with an inten- sified antitumor effect, immune profiling of Lewis lung cancer models demonstrated lower PD-L1 expression on tumor surfaces (Fig. 6d) and more tumor-infiltrating CD8+ T cells in mice receiving the combined THZ1 and antiPD-1 therapy (Fig. 6f). Specifically, the ...
A mouse model with reconstituted human immune system components (huNSG mice) was constructed to explore the role of exosomal circCCAR1 in the resistance to anti-PD1 therapy in HCC. Results Increased circCCAR1 levels existed in tumor tissues and exosomes in the plasma of HCC patients, in the...
The present study integrates spatial transcriptomics, bulk transcriptomics and proteomics, revealing a strong link between the metabolite succinyl-CoA and tumor immunity as well as the efficacy of anti-programmed cell death protein-1 (PD-1) therapy in patients with melanoma. Elevated succinyl-CoA ...
CXCR4 inhibition favors T effector access to TME also in a more immune resistant model such as B16-hCXCR4. Pep R also reduced Treg infiltration in MC38 and B16-hCXCR4 tumors rendering the TME more immunoresponsive to anti-PD-1 therapy, as previously reported for B16 melanoma [39]. ...
CircCCAR1 promotes the resistance of HCC to anti-PD1 therapy To explore the role of circCCAR1 in anti-PD1 therapy, a HuNSG mouse xenograft model was constructed. Exosomal circCCAR1 in the peripheral blood from HuNSG mice bearing xenografts derived from circCCAR1-overexpressing HCCLM3 cells...